BNO.AX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (24 Aug 2023 @ 12:34):

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers...

Stats
今日成交量	4.41M
平均成交量	2.86M
市值	13.22M
EPS	$-0.00322 ( Q1 \| 2020-09-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450 (Sector) 0 (Industry) 0
ATR14	$0.00300 (30.00%)

ACW.AX 4.84%

ADO.AX 5.00%

AGH.AX 4.35%

ANP.AX -4.92%

ATH.AX 25.00%

AVE.AX -33.33%

BIT.AX 2.63%

BNO.AX -10.00%

BOT.AX -8.70%

CAN.AX 7.14%

CPH.AX 0.00%

CSL.AX -0.88%

CTE.AX 0.81%

CUV.AX -0.65%

CYP.AX 0.00%

DXB.AX 3.92%

ECS.AX 5.88%

EOF.AX -6.67%

GSS.AX 5.56%

IDT.AX -4.55%

IMC.AX -5.68%

IMM.AX 5.08%

IMU.AX -3.51%

IXC.AX 0.00%

KZA.AX 9.59%

LCT.AX 7.14%

LGP.AX 5.26%

MSB.AX 1.01%

MVP.AX -2.47%

MXC.AX 2.44%

NEU.AX -4.98%

NOX.AX 0.00%

NSB.AX 0.00%

OCC.AX 2.82%

OPT.AX -1.43%

OSL.AX 25.00%

PAA.AX 0.00%

PAB.AX 14.29%

PAR.AX 13.73%

PBP.AX 0.00%

PIQ.AX -1.14%

PTX.AX 5.26%

PXS.AX 3.70%

PYC.AX 0.00%

RAC.AX -0.27%

RCE.AX 5.26%

SPL.AX -3.16%

TLX.AX -3.00%

VBS.AX -1.30%

音量相关性

長: -0.41 (neutral)

短: 0.00 (neutral)

Signal:(42.46) Neutral

Bionomics Ltd 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Bionomics Ltd 相关性 - 货币/商品

0.59
( weak )

0.57
( weak )

0.00
( neutral )

0.21
( neutral )

Bionomics Ltd 财务报表

Annual	2022
营收:	$22 047.00
毛利润:	$22 047.00 (100.00 %)
EPS:	$0

FY	2022
营收:	$22 047.00
毛利润:	$22 047.00 (100.00 %)
EPS:	$0

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$0

FY	2022
营收:	$263 634
毛利润:	$263 634 (100.00 %)
EPS:	$-0.0161

Financial Reports:

No articles found.

Bionomics Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Bionomics Ltd

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.